Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Feb 13, 2018 SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter financial results on T...
Feb 7, 2018 -- Company presentation scheduled for February 15, 2018 at 9:30 a.m. ET -- SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-n...
Jan 30, 2018 -- McPherson, Kansas facility compliance status amended to Voluntary Action Indicated (VAI) -- -- VAI status provides a clear regulatory path for potential approval of plazomicin out of McPherson facility -- SOUTH SAN FRANCISCO, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE)...
Jan 25, 2018 SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on January 19, 2018, the compensation committee of the Company's board of di...
Jan 3, 2018 — Company presentation scheduled for January 11, 2018 — SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, tod...
Jan 2, 2018 -- C-Scape was well tolerated across all doses studied in Phase 1 trial, with no drug-drug interaction between the previously approved compounds when dosed in combination -- -- C-Scape is a combination of ceftibuten and clavulanate and exhibits potent microbiological activity, pre-clinic...
Jan 2, 2018 -- Investigational drug has potential to treat certain MDR gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) -- -- FDA sets action date of June 25, 2018 -- SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:...
Dec 22, 2017 SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on December 20, 2017, the compensation committee of the Company's board of d...
Dec 11, 2017 - Dr. Kenneth Hillan to become President, R&D - - Succession designed to lead Achaogen through next phase of growth as a commercial-stage company - - Transition effective January 1, 2018 - SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NE...
Nov 30, 2017 SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that management will be hosting investor meetings at the Guggenheim Securities ...
Page:
1
... NextLast
= add release to Briefcase